Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

Dear Editor, Blastic plasmacytoid dendritic cell neoplasm (BPDCN), formerly known as agranular CD4 SP + sp /CD56 SP + sp hematodermic neoplasm or blastic natural killer (NK) cell lymphoma was officially recognized as a distinct entity in the 2016 revision of the World Health Organization (WHO) classification of myeloid malignancies [[1]]. In an open-label clinical trial with tagraxofusp in 47 patients with BPDCN, response rates were 90 and 67% among treatment naïve and relapsed patients, respectively [[5]]. 1Overall survival of Mayo Clinic patients with blastic plasmacytoid dendritic cell neoplasm.a Overall survival of 55 patients with blastic plasmacytoid dendritic cell neoplasm stratified by allogeneic stem cell transplant. b Overall survival of 36 patients with blastic plasmacytoid dendritic cell neoplasm stratified by normal vs abnormal karyotype. [Extracted from the article]